Overview

Ranibizumab for Myopic Neovascularization

Status:
Unknown status

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).

Phase:

Phase 4

Details

Lead Sponsor:

Instituto de Olhos de Goiania

Treatments:

Ranibizumab